# A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

> **NCT06616974** · PHASE2 · RECRUITING · sponsor: **Tectonic Therapeutic** · enrollment: 180 (estimated)

## Conditions studied

- Pulmonary Hypertension
- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** TX000045- Dose A
- **DRUG:** TX000045- Dose B
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06616974
- **Lead sponsor:** Tectonic Therapeutic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-04
- **Primary completion:** 2026-10-09
- **Final completion:** 2026-11-20
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06616974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06616974, "A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06616974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*